Argenx announces positive phase 3 data from advance trial of vyvgart® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia

Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with vyvgart treatment compared to placebo (p=0.0316) ; responders observed across patient types regardless of prior therapy or disease severity
ARGX Ratings Summary
ARGX Quant Ranking